HRC

Summary

HRC (histidine rich calcium binding protein, HGNC:5178) is a protein-coding gene on chromosome 19q13.33, encoding Sarcoplasmic reticulum histidine-rich calcium-binding protein (P23327). May play a role in the regulation of calcium sequestration or release in the SR of skeletal and cardiac muscle.

This gene encodes a luminal sarcoplasmic reticulum protein identified by its ability to bind low-density lipoprotein with high affinity. The protein interacts with the cytoplasmic domain of triadin, the main transmembrane protein of the junctional sarcoplasmic reticulum (SR) of skeletal muscle. The protein functions in the regulation of releasable calcium into the SR.

Source: NCBI Gene 3270 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 117 total — 1 likely-pathogenic
• MANE Select transcript: NM_002152

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5178
Approved symbol	HRC
Name	histidine rich calcium binding protein
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Aliases	MGC133236
Ensembl gene	ENSG00000130528
Ensembl biotype	protein_coding
OMIM	142705
Entrez	3270

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 retained_intron

ENST00000252825, ENST00000595167, ENST00000595625, ENST00000598858, ENST00000867157, ENST00000867158, ENST00000966424, ENST00000966425

RefSeq mRNA: 1 — MANE Select: NM_002152 NM_002152

CCDS: CCDS12759

Canonical transcript exons

ENST00000252825 — 6 exons

Exon	Start	End
ENSE00000896142	49153407	49155396
ENSE00000896143	49153261	49153331
ENSE00000896144	49152310	49152378
ENSE00000896147	49152004	49152058
ENSE00000896150	49151517	49151553
ENSE00003090022	49151198	49151332

Expression profiles

Bgee: expression breadth ubiquitous, 178 present calls, max score 99.61.

FANTOM5 (CAGE): breadth broad, TPM avg 5.6527 / max 958.9746, expressed in 355 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181992	5.6527	355

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	99.61	gold quality
left ventricle myocardium	UBERON:0006566	99.21	gold quality
heart left ventricle	UBERON:0002084	99.18	gold quality
cardiac ventricle	UBERON:0002082	99.17	gold quality
right atrium auricular region	UBERON:0006631	99.09	gold quality
cardiac atrium	UBERON:0002081	98.98	gold quality
gastrocnemius	UBERON:0001388	98.82	gold quality
heart right ventricle	UBERON:0002080	98.75	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.74	gold quality
gluteal muscle	UBERON:0002000	98.42	gold quality
cardiac muscle of right atrium	UBERON:0003379	97.90	gold quality
muscle of leg	UBERON:0001383	97.82	gold quality
myocardium	UBERON:0002349	97.76	gold quality
triceps brachii	UBERON:0001509	97.71	gold quality
muscle organ	UBERON:0001630	97.43	gold quality
skeletal muscle organ	UBERON:0014892	97.43	gold quality
heart	UBERON:0000948	96.90	gold quality
skeletal muscle tissue	UBERON:0001134	96.50	gold quality
quadriceps femoris	UBERON:0001377	96.40	gold quality
vastus lateralis	UBERON:0001379	96.36	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	96.14	gold quality
biceps brachii	UBERON:0001507	95.77	gold quality
diaphragm	UBERON:0001103	95.01	gold quality
deltoid	UBERON:0001476	94.96	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.43	gold quality
muscle tissue	UBERON:0002385	94.40	gold quality
tibialis anterior	UBERON:0001385	94.25	gold quality
vena cava	UBERON:0004087	91.58	silver quality
body of tongue	UBERON:0011876	89.98	silver quality
popliteal artery	UBERON:0002250	86.16	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.94

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SOX15, SOX2

Literature-anchored findings (GeneRIF, showing 12)

• Results identify the HRC enhancer as the first MEF2-dependent, CArG-motif-independent transcriptional target in smooth muscle and represent the first analysis of the transcriptional regulation of a sarcoplasmic reticulum gene in vivo. (PMID:15082771)
• alterations in expression levels of HRC are associated with impaired cardiac SR Ca homeostasis and contractile function. (PMID:15191886)
• Histidine-rich Ca-binding protein may play a key role in the regulation of SR Ca cycling through its direct interactions with SERCA2 and triadin, mediating a fine cross talk between SR Ca uptake and release in the heart. (PMID:17526652)
• The Ser96Ala genetic variant of HRC is associated with life-threatening ventricular arrhythmias in idiopathic DCM and may serve as an independent predictor of susceptibility to arrhythmogenesis in the setting of DCM. (PMID:18617481)
• findings suggest that aberrant sarcoplasmic reticulum Ca2+ release and increased susceptibility to delayed afterdepolarizations underlie triggered arrhythmic activity in Ala96 HRC carriers (PMID:24125847)
• The S96A HRC mutation disrupts the Ca2+ -microdomain around the RyR2, as it alters the Ca2+ -dependent association of RyR2 and HRC. (PMID:24805197)
• Up-regulation of histidine-rich calcium binding protein promotes tumor metastasis in hepatocellular carcinoma and is mediated by SATB1. (PMID:25762622)
• this study demonstrates a role of HRC in promoting hepatocellular carcinoma (HCC) growth, besides its role in inducing HCC metastasis, and highlights HRC as a promising intervention target for HCC. (PMID:26176291)
• Histidine-rich Ca-binding protein (HRC) was phosphorylated by family with sequence similarity 20C (Fam20C) both in vitro and in vivo. (PMID:28784772)
• Ser96Ala genetic variant of the human histidine-rich calcium-binding protein is associated with recurrence in paroxysmal atrial fibrillation. (PMID:30840693)
• HRC promotes anoikis resistance and metastasis by suppressing endoplasmic reticulum stress in hepatocellular carcinoma. (PMID:34400882)
• Lack of Evidence for the Role of the p.(Ser96Ala) Polymorphism in Histidine-Rich Calcium Binding Protein as a Secondary Hit in Cardiomyopathies. (PMID:37958923)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	hrc	ENSDARG00000045947
mus_musculus	Hrc	ENSMUSG00000038239
rattus_norvegicus	Hrc	ENSRNOG00000020719

Protein

Protein identifiers

Sarcoplasmic reticulum histidine-rich calcium-binding protein — P23327 (reviewed: P23327)

All UniProt accessions (3): P23327, M0QY84, M0QZ43

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in the regulation of calcium sequestration or release in the SR of skeletal and cardiac muscle.

Subcellular location. Sarcoplasmic reticulum lumen.

Similarity. Belongs to the HRC family.

RefSeq proteins (1): NP_002143* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR015666	HRC	Family
IPR019552	Hist_rich_Ca-bd	Repeat

Pfam: PF10529

UniProt features (43 total): compositionally biased region 15, repeat 10, modified residue 8, region of interest 5, sequence variant 3, signal peptide 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P23327-F1	50.20	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 76, 119, 145, 333, 358, 431, 494, 567

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-8957275	Post-translational protein phosphorylation
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 146 (showing top): MYOGENIN_Q6, GOBP_CIRCULATORY_SYSTEM_PROCESS, DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_UP, GOBP_RELAXATION_OF_CARDIAC_MUSCLE, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP, TGACCTY_ERR1_Q2, MODULE_329, CAGCTG_AP4_Q5, GNF2_MYL3, GOBP_REGULATION_OF_CARDIAC_MUSCLE_CONTRACTION_BY_REGULATION_OF_THE_RELEASE_OF_SEQUESTERED_CALCIUM_ION, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_STRIATED_MUSCLE_CONTRACTION, MODULE_120

GO Biological Process (10): regulation of heart rate (GO:0002027), muscle contraction (GO:0006936), positive regulation of heart rate (GO:0010460), regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum (GO:0010880), regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion (GO:0010881), positive regulation of heart contraction (GO:0045823), regulation of cytosolic calcium ion concentration (GO:0051480), regulation of cell communication by electrical coupling involved in cardiac conduction (GO:1901844), positive regulation of relaxation of cardiac muscle (GO:1901899), regulation of calcium ion transmembrane transport (GO:1903169)

GO Molecular Function (4): calcium ion binding (GO:0005509), transmembrane transporter binding (GO:0044325), ATPase binding (GO:0051117), protein binding (GO:0005515)

GO Cellular Component (7): mitochondrion (GO:0005739), endoplasmic reticulum (GO:0005783), endoplasmic reticulum lumen (GO:0005788), cytosol (GO:0005829), Z disc (GO:0030018), sarcoplasmic reticulum lumen (GO:0033018), sarcoplasmic reticulum (GO:0016529)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Metabolism of proteins	2
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	3
regulation of heart contraction	2
intracellular membrane-bounded organelle	2
endoplasmic reticulum	2
cellular anatomical structure	2
regulation of biological quality	1
muscle system process	1
regulation of heart rate	1
positive regulation of heart contraction	1
release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	1
regulation of release of sequestered calcium ion into cytosol	1
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	1
regulation of cardiac muscle contraction by calcium ion signaling	1
heart contraction	1
positive regulation of blood circulation	1
intracellular calcium ion homeostasis	1
regulation of cell communication by electrical coupling	1
cell communication by electrical coupling involved in cardiac conduction	1
relaxation of cardiac muscle	1
positive regulation of relaxation of muscle	1
regulation of relaxation of cardiac muscle	1
regulation of calcium ion transport	1
calcium ion transmembrane transport	1
regulation of monoatomic cation transmembrane transport	1
metal ion binding	1
protein binding	1
enzyme binding	1
binding	1
endomembrane system	1
intracellular organelle lumen	1
I band	1
endoplasmic reticulum lumen	1
sarcoplasmic reticulum	1
sarcoplasm	1

Protein interactions and networks

STRING

1280 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HRC	TRDN	Q13061	893
HRC	SULT2A1	Q06520	817
HRC	ATP2A2	P16614	692
HRC	APOC2	P02655	654
HRC	KLK4	Q9Y5K2	654
HRC	HSF5	Q4G112	570
HRC	DRC8	Q5VUJ9	517
HRC	AGFG1	P52594	462
HRC	ASPH	Q12797	430
HRC	MYBPH	Q13203	424
HRC	RYR2	Q92736	409
HRC	HSF4	Q9ULV5	405
HRC	EDIL3	O43854	403
HRC	HSFY1	Q96LI6	401
HRC	KLHL30	Q0D2K2	367

IntAct

13 interactions, top by confidence:

A	B	Type	Score
HRC	ZNF699	psi-mi:“MI:0915”(physical association)	0.560
HRC	ZNF791	psi-mi:“MI:0914”(association)	0.530
Ryr2	HRC	psi-mi:“MI:2364”(proximity)	0.520
HRC	Ryr2	psi-mi:“MI:0403”(colocalization)	0.520
Ryr2	HRC	psi-mi:“MI:0915”(physical association)	0.520
JUP	HRC	psi-mi:“MI:0915”(physical association)	0.510
Trdn	HRC	psi-mi:“MI:0915”(physical association)	0.400
TRDN	HRC	psi-mi:“MI:0915”(physical association)	0.400
HRC	ZNF699	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (12): ZNF101 (Affinity Capture-MS), ZNF430 (Affinity Capture-MS), ZNF791 (Affinity Capture-MS), POF1B (Affinity Capture-MS), ZNF699 (Two-hybrid), TRDN (Reconstituted Complex), ZNF430 (Affinity Capture-MS), ZNF791 (Affinity Capture-MS), ZNF101 (Affinity Capture-MS), HRC (PCA), HRC (Proximity Label-MS), HRC (Proximity Label-MS)

ESM2 similar proteins: A0A0J9YWL9, A0A0J9YY54, A6QL64, B4DH59, D3YVF0, D3YZV8, D5LGE0, E2RYF7, E9Q6E9, O15069, O35930, O43493, O77733, O88799, P0DKJ7, P0DKJ8, P10322, P16225, P23327, P24587, P53353, P62521, Q14242, Q28139, Q2EG98, Q3BBV2, Q4ZJZ1, Q4ZJZ3, Q5HY64, Q5JPF3, Q5JRC9, Q5XHX6, Q62170, Q6JHY2, Q6P902, Q6ZQX7, Q7M4S9, Q86T75, Q8BVC1, Q8N2N9

Diamond homologs: P16230, P23327

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
FAM20C	“up-regulates activity”	HRC	phosphorylation
HRC	“down-regulates activity”	ATP2A2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

117 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	90
Likely benign	18
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2582780	Single allele	Likely pathogenic

SpliceAI

637 predictions. Top by Δscore:

Variant	Effect	Δscore
19:49151333:CTGGA:C	acceptor_loss	1.0000
19:49151334:T:C	acceptor_loss	1.0000
19:49152054:CAGTG:C	acceptor_gain	1.0000
19:49153404:TA:T	donor_loss	1.0000
19:49153405:A:AC	donor_gain	1.0000
19:49153405:AC:A	donor_gain	1.0000
19:49153406:C:CC	donor_gain	1.0000
19:49153406:C:CG	donor_loss	1.0000
19:49153406:CC:C	donor_gain	1.0000
19:49153406:CCT:C	donor_gain	1.0000
19:49151331:CC:C	acceptor_gain	0.9900
19:49151332:CC:C	acceptor_gain	0.9900
19:49151333:C:CC	acceptor_gain	0.9900
19:49151515:A:AC	donor_gain	0.9900
19:49151516:C:CC	donor_gain	0.9900
19:49152059:C:CC	acceptor_gain	0.9900
19:49152374:CATCG:C	acceptor_gain	0.9900
19:49152377:CG:C	acceptor_gain	0.9900
19:49152379:C:CC	acceptor_gain	0.9900
19:49153406:CCTG:C	donor_gain	0.9900
19:49153406:CCTGT:C	donor_gain	0.9900
19:49153424:T:A	donor_gain	0.9900
19:49151328:GGGCC:G	acceptor_gain	0.9800
19:49151329:GGCC:G	acceptor_gain	0.9800
19:49151330:GCC:G	acceptor_gain	0.9800
19:49151330:GCCC:G	acceptor_gain	0.9800
19:49151331:CCC:C	acceptor_gain	0.9800
19:49151998:GCTCA:G	donor_loss	0.9800
19:49152000:TCACC:T	donor_loss	0.9800
19:49152001:CA:C	donor_loss	0.9800

AlphaMissense

4801 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:49152047:G:C	F661L	0.994
19:49152047:G:T	F661L	0.994
19:49152049:A:G	F661L	0.994
19:49153265:C:T	C633Y	0.994
19:49152314:C:G	C656S	0.993
19:49152315:A:T	C656S	0.993
19:49152374:C:G	C636S	0.993
19:49152375:A:T	C636S	0.993
19:49153265:C:G	C633S	0.993
19:49153266:A:T	C633S	0.993
19:49152037:A:G	C665R	0.992
19:49152045:C:T	C662Y	0.992
19:49152048:A:C	F661C	0.992
19:49152350:C:G	C644S	0.992
19:49152351:A:T	C644S	0.992
19:49152365:C:G	C639S	0.992
19:49152366:A:T	C639S	0.992
19:49152044:G:C	C662W	0.991
19:49152024:C:T	C669Y	0.990
19:49152054:C:T	C659Y	0.990
19:49152356:C:G	C642S	0.990
19:49152357:A:T	C642S	0.990
19:49152054:C:G	C659S	0.989
19:49152055:A:T	C659S	0.989
19:49152315:A:G	C656R	0.989
19:49152323:C:G	C653S	0.989
19:49152323:C:T	C653Y	0.989
19:49152324:A:T	C653S	0.989
19:49152350:C:T	C644Y	0.989
19:49152366:A:G	C639R	0.989

dbSNP variants (sampled 300 via entrez): RS1000176076 (19:49155832 T>G), RS1001165739 (19:49152463 C>G,T), RS1002428648 (19:49151691 C>G), RS1003238759 (19:49151925 A>G,T), RS1003597316 (19:49152146 G>A), RS1003774442 (19:49156959 C>A,G), RS1004346812 (19:49156208 T>C,G), RS1004648709 (19:49150895 T>A,C), RS1004674446 (19:49152737 T>A,C), RS1005005058 (19:49152964 C>G), RS1005416189 (19:49154929 G>C,T), RS1005601290 (19:49151837 G>A,C), RS1006090874 (19:49151671 T>C), RS1006615095 (19:49150939 T>G), RS1006831164 (19:49153316 T>C)

Disease associations

OMIM: gene MIM:142705 | disease phenotypes: MIM:113900, MIM:604559, MIM:601144

GenCC curated gene-disease

Mondo (3): progressive familial heart block, type 1A (MONDO:0007240), progressive familial heart block type IB (MONDO:0011474), Brugada syndrome (MONDO:0015263)

Orphanet (2): Brugada syndrome (Orphanet:130), Hereditary progressive cardiac conduction defect (Orphanet:871)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D053840	Brugada Syndrome	C14.280.067.322; C14.280.123.250; C16.320.100
D002037	Bundle-Branch Block	C14.280.067.558.323; C14.280.123.500.323; C23.550.073.425.100
C567037	Progressive Familial Heart Block, Type Ib (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Doxorubicin	affects expression, decreases expression	4
Daunorubicin	decreases expression	2
Mitoxantrone	decreases expression	2
bisphenol A	increases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
2,7-dihydroxynaphthalene	decreases expression	1
incobotulinumtoxinA	decreases expression	1
Decitabine	affects expression	1
Leflunomide	increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation, increases methylation	1
Caffeine	decreases phosphorylation	1
Cannabidiol	decreases expression	1
Cisplatin	affects expression	1
Folic Acid	decreases expression	1
Toluene	decreases methylation, increases expression	1
Triclosan	decreases expression	1
Vitamin D	decreases reaction, increases expression, increases phosphorylation	1
1-Methyl-4-phenylpyridinium	increases expression	1

Clinical trials (associated diseases)

43 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00702117	PHASE4	COMPLETED	Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias
NCT00701077	PHASE3	TERMINATED	DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome
NCT00927732	PHASE3	TERMINATED	Hydroquinidine Versus Placebo in Patients With Brugada Syndrome
NCT02933437	PHASE2	UNKNOWN	The Response To Ajmaline Provocation in Healthy Subjects
NCT07146880	PHASE2	NOT_YET_RECRUITING	Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT02014961	Not specified	UNKNOWN	Worm Study: Modifier Genes in Sudden Cardiac Death
NCT02052765	Not specified	COMPLETED	AnalyST & Brugada Syndrome - Feasibility Study
NCT02302274	Not specified	COMPLETED	Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome
NCT02344277	Not specified	COMPLETED	Evaluation of Subcutaneous Implantable Cardiac Defibrillator in Brugada Patients
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02641431	Not specified	COMPLETED	Epicardial Ablation in Brugada Syndrome
NCT02704416	Not specified	COMPLETED	Ablation in Brugada Syndrome for the Prevention of VF
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03435393	Not specified	UNKNOWN	Ripple Mapping for Epicardial Mapping of Brugada Syndrome
NCT03485508	Not specified	UNKNOWN	The Brugada Syndrome: a Follow-up Study
NCT03491475	Not specified	UNKNOWN	Echocardiography During Ajmaline Test
NCT03524079	Not specified	COMPLETED	Right Ventricle Morphology and Hemodynamics in BrS
NCT03764592	Not specified	COMPLETED	VF Mapping in Brugada and Early Repolarization Syndromes
NCT03775954	Not specified	RECRUITING	Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
NCT03992677	Not specified	COMPLETED	Feasibility of Improving Risk Stratification in Brugada Syndrome
NCT04124237	Not specified	COMPLETED	Long Term Monitoring for Risk of Sudden Death
NCT04232787	Not specified	UNKNOWN	Southeast Asian Brugada Syndrome Cohort
NCT04257994	Not specified	RECRUITING	Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders
NCT04420078	Not specified	COMPLETED	Brugada Ablation of VF Substrate Ongoing MultiCenter Registry
NCT04580992	Not specified	UNKNOWN	Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial
NCT04650009	Not specified	COMPLETED	Physical Activity in Children With Inherited Cardiac Diseases
NCT04712136	Not specified	COMPLETED	Healthy-related Quality of Life and Physical Activity of Children With Cardiac Malformations
NCT04808193	Not specified	UNKNOWN	European Perioperative Brugada Survey
NCT05048602	Not specified	UNKNOWN	Drug-induced Brugada Syndrome Research Database
NCT05274646	Not specified	COMPLETED	Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A
NCT05283759	Not specified	RECRUITING	UZ Brussel HRMC Registry of Brugada Syndrome
NCT05521451	Not specified	RECRUITING	Clinical Cohort Study - TRUST
NCT05643209	Not specified	RECRUITING	Brugada Syndrome Substrate Characterization and Ablation
NCT05685134	Not specified	COMPLETED	Epicardial Radiofrequency Catheter Ablation in Patients With Brugada Syndrome
NCT06376552	Not specified	COMPLETED	Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome
NCT06546137	Not specified	RECRUITING	National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil’s Unified Health System Through a Multicenter Registry
NCT06567639	Not specified	COMPLETED	High Density Mapping in Brugada Syndrome
NCT06647927	Not specified	RECRUITING	GenLab: Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis
NCT06653504	Not specified	COMPLETED	The Conus Brugada Syndrome Study